Ulrike Leiter

Prof. Dr. Ulrike Leiter

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2016 in The Lancet Oncology
Verified
Journal Article
Closed access
ULUlrike Leiter
Ulrike Leiter
RSRudolf Stadler
Rudolf Stadler
CMCornelia Mauch
Cornelia Mauch
WHWerner Hohenberger
Werner Hohenberger
NBNorbert Brockmeyer
Norbert Brockmeyer
G(German Dermatologic Cooperative Oncology Group (DeCOG)
German Dermatologic Cooperative Oncology Group (DeCOG)


1 January 2009 in Clinics in Dermatology
Verified
Journal Article
Closed access
Claus GarbeClaus Garbe
Claus Garbe
ULUlrike Leiter
Ulrike Leiter

1 January 2014
Verified
Book Chapter
Closed access
PDF file
ULUlrike Leiter
Ulrike Leiter
TEThomas Eigentler
Thomas Eigentler
Claus GarbeClaus Garbe
Claus Garbe

28 July 2023 in European Journal of Cancer
Verified
Journal Article
Open access
KPKetty Peris
Ketty Peris
MFMaria Concetta Fargnoli
Maria Concetta Fargnoli
RKRoland Kaufmann
Roland Kaufmann
PAPetr Arenberger
Petr Arenberger
LBLars Bastholt
Lars Bastholt
Claus GarbeClaus Garbe
Claus Garbe
Basal cell carcinoma (BCC) is the most common malignant tumour in white populations. Multidisciplinary experts from European Association of Dermato-Oncology (EADO), European Dermatology Forum, European Society for Radiotherapy and Oncology (ESTRO), Union Européenne des Médecins Spécialistes, and the European Academy of Dermatology and Venereology developed updated recommendations on diagnosis and treatment of BCC. BCCs were categorised into 'easy-to-treat' (common) and 'difficult-to-treat' according to the new EADO clinical classification. Diagnosis is based on clinico-dermatoscopic features, although histopathological confirmation is mandatory in equivocal lesions. The first-line treatment of BCC is complete surgery. Micrographically controlled surgery shall be offered in high-risk and recurrent BCC, and BCC located on critical anatomical sites. Topical therapies and destructive approaches can be considered in patients with low-risk superficial BCC. Photodynamic therapy is an effective treatment for superficial and low-risk nodular BCCs. Management of 'difficult-to-treat' BCCs should be discussed by a multidisciplinary tumour board. Hedgehog inhibitors (HHIs), vismodegib or sonidegib, should be offered to patients with locally advanced and metastatic BCC. Immunotherapy with anti-PD1 antibodies (cemiplimab) is a second-line treatment in patients with a progression of disease, contraindication, or intolerance to HHI therapy. Radiotherapy represents a valid alternative in patients who are not candidates for or decline surgery, especially elderly patients. Electrochemotherapy may be offered when surgery or radiotherapy is contraindicated. In Gorlin patients, regular skin examinations are required to diagnose and treat BCCs at an early stage. Long-term follow-up is recommended in patients with high-risk BCC, multiple BCCs, and Gorlin syndrome.

21 June 2004 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
ULUlrike Leiter
Ulrike Leiter
FMFriedegund Meier
Friedegund Meier
BSBirgit Schittek
Birgit Schittek
Claus GarbeClaus Garbe
Claus Garbe